Celularity Inc.
Florham Park, NJ, US· latest recorded location
Celularity Inc. is named on 19 US grants and 72 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 19
- Published applications
- 72
- Inventors
- 122
- Granted in 2026 so far
- 0
- Most recent grant
- 11 Jul 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 1 | 0 |
| 2018 | 6 | 8 |
| 2019 | 4 | 13 |
| 2020 | 3 | 10 |
| 2021 | 3 | 10 |
| 2022 | 1 | 12 |
| 2023 | 1 | 9 |
| 2024 | 0 | 1 |
| 2025 | 0 | 3 |
| 2026 | 0 | 4 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 91 documents
- A61KMedicines and medical preparations73
- A61PTherapeutic uses of medicines71
- C12NMicroorganisms or enzymes64
- A61LMethods or apparatus for sterilising materials or objects in general12
- C07KPeptides12
- A01NPreservation of bodies of humans or animals or plants or parts thereof6
- A61QSpecific use of cosmetics or similar toiletry preparations5
- G02BOptical elements, systems or apparatus4
- H01SDevices using the process of light amplification by stimulated emission of radiation4
- A01KAnimal husbandry3
Recent patents
- Use of placental stem cells in treatment of acute kidney injury11 Jul 2023US 11,696,930 B2
- Enhanced placental stem cells and uses thereof29 Nov 2022US 11,512,282 B2
- Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells23 Nov 2021US 11,180,731 B2
- Placenta-derived adherent cell exosomes and uses thereof16 Nov 2021US 11,173,182 B1
- Treatment of pain using placental stem cells17 Aug 2021US 11,090,339 B2
- Dermal rejuvenation composition comprising placenta derived biomaterial and uses thereof23 Jul 2026US 2026/0207677 A1
- Compositions and methods for treating cancer2 Jul 2026US 2026/0183328 A1
- Human Placental Derived Natural Killer Cells with High Affinity and Cleavage Resistant CD16 and Secreted IL-15, and uses thereof28 May 2026US 2026/0144871 A1
- Method for modulating glucagon-like peptide 1 (glp-1) agonist induced muscle loss1 Jan 2026US 2026/0000712 A1
- Cleavage resistant cd16 constructs and uses thereof25 Sep 2025US 2025/0295776 A1
Most cited
By later US patents
- Cell composition and methods of making the same5US 10,104,880 B22018
- CD34+,CD45−placental stem cell-enriched cell populations4US 10,494,607 B22019
- Methods and compositions for treatment of bone defects with placental cell populations2US 10,105,399 B22018
- Human placental collagen compositions, and methods of making and using the same2US 9,775,886 B22017
- Method of collecting placental stem cells1US 10,113,146 B22018